Gilead
10 Dec 2020
Trial Summary
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
Acronym:
Gilead
ACTRN/NCT /ethics:
NCT02536300
Scientific title:
Dose optimization of idelalisib in follicular lymphoma
Sponsor / Cooperative group:
Gilead Sciences
Trial & Patient Characteristics
| Cancer Type | Lymphoma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Follicular lymphoma |
| Cancer Stage | All stages |
| Anticipated Start Date | 2016-01-14 |
| Anticipated End Date | 2030-11-01 |
Participating Hospitals
| Hospital | Calvary Central Districts Hospital |
|---|---|
| Clinical Trial Coordinator | Julie Rowe |
| julie.rowe@calvarycare.org.au | |
| Phone | 08 8239 9536 |
| Principal Investigator | Dr Wilfrid Jaksic |
| Recruitment Status | Recruiting |